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A B S T R A C T
Invasive fungal infection (IFI) is a rare but serious complication of traumatic injury. The purpose of this
article is to review the epidemiology, natural history, mycology, risk factors, diagnosis, treatment, and
outcomes associated with post-traumatic IFI in military and civilian populations. The epidemiology of
post-traumatic IFI is poorly characterized, but incidence appears to be rising. Patients often suffer from
severe injuries and require extensive medical interventions. Fungi belonging to the order Mucorales are
responsible for most post-traumatic IFI in both civilian and military populations. Risk factors differ
between these cohorts but include speciﬁc injury patterns and comorbidities. Diagnosis of post-
traumatic IFI typically follows positive laboratory results in the appropriate clinical context. The gold
standard of treatment is surgical debridement in addition to systemic antifungal therapy. Patients with
post-traumatic IFI may be at greater risk of amputation, delays in wound healing, hospital complications,
and death as compared to trauma patients who do not develop IFI. More research is needed to understand
the factors surrounding the development and management of post-traumatic IFI to reduce the signiﬁcant
morbidity and mortality associated with this disease.
© 2017 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Introduction
Invasive fungal infections (IFI) are a rare but serious complica-
tion of traumatic injury characterized by fungal angioinvasion and
resultant vessel thrombosis and tissue necrosis (Alonso et al.,
2006; Spellberg et al., 2005). In contrast to other settings, post-
traumatic IFI occurs through direct inoculation of tissue with
spores at the site of injury (Bilal et al., 2016). Fungi may then take
advantage of an acidemic, iron-rich environment to proliferate and
invade vessels through hyphae growth. Patients with post-
traumatic IFI suffer poor outcomes from the aggressive nature
of the infection and from delays in diagnosis and appropriate
management (Neblett Fanfair et al., 2012). Signiﬁcant gaps in the
literature exist, with large-scale cohorts and comparative studies
curbed by the scarcity of cases. Nevertheless, a growing body of
evidence drawn from case series, cohorts, and case-control studies
has accumulated over the past several decades such that clinicians
and researchers can begin to gain an understanding of the clinical
course and consequences of developing post-traumatic IFI.
The aim of this review is to summarize the epidemiology,
clinical presentation, microbiology, diagnosis, management, and
clinical outcomes in military and civilian trauma patients with IFI.
When possible, we will focus on IFI occurring as a direct result of
soft tissue injury rather than delayed or chronic progressing
infection, as the latter group likely represents a different
pathogenic pathway. Additionally, we will highlight areas lacking




During the wars in Iraq and Afghanistan, IFI emerged as a
signiﬁcant complication of combat-related injury. A review of the
U.S. Department of Defense Joint Theater Trauma Registry
identiﬁed fungal infection by ICD-9 codes in 0.44% of combat
trauma patients, although these codes were not speciﬁc to IFI and
candidiasis, both invasive and non-invasive, accounted for the
majority of infections (Murray et al., 2011). Subsequently, analyses
of combat-injured military personnel evacuated from Afghanistan
found an overall IFI incidence rate of 6.8% (Rodriguez et al., 2014a),
with incidence increasing over the period of observation (War-
kentien et al., 2012). These data were based on the Trauma
Infectious Disease Outcomes Study (TIDOS), representing a subset
of 1,133 injured soldiers evacuated from Afghanistan between
2009 and 2011. The improved sensitivity and accuracy of IFI
identiﬁcation afforded by TIDOS likely contributed to these starkly
different incidence estimates.
Demographically, the military population affected by IFI is
consistent with the underlying population of young healthy adult
soldiers (Table 1). Cohort patients were all male, with a median age
between 22 and 24 years old, and most had no underlying medical
conditions (Paolino et al., 2012; Lloyd et al., 2014).
Civilian
The epidemiology of post-traumatic IFI in the heterogeneous
civilian population is less well-deﬁned. Observational studies have
varying IFI deﬁnitions and patient characteristics, and many are
conﬁned to cases of mucormycosis only, which have an annual
incidence of approximately 0.43–1.7 cases per million persons
(Bitar et al., 2009; Bouza et al., 2006; Torres-Narbona et al., 2007).
Traumatic injury accounts for up to 21% of these cases overall and
59% of primary cutaneous mucormycosis (Llorente et al., 2011;
Skiada et al., 2011; Pagano et al., 2009; Lanternier et al., 2012;
Roden et al., 2005; Skiada and Petrikkos, 2009; Skiada et al., 2012;
Kaushik, 2012). Incidence of post-traumatic IFI due to all
organisms, however, is poorly characterized. A prospective study
in Lebanon found that the rate of fungal infection in patients
injured by cluster munition explosions was 2.6% (Fares et al., 2013).
Two retrospective studies found IFI to occur in 3.1% of upper
extremity wounds and 15% of corn picker injuries (Moran et al.,
2006a; Obradovic-Tomasev et al., 2016). These studies, however,
were circumscribed to a speciﬁc injury type and are not likely to be
generalizable. Vitrat-Hincky et al. (2009) identiﬁed 75 cases of
post-traumatic ﬁlamentous fungal infection in the literature and
their own hospital records between 1985 and 2008, most often due
to either trafﬁc accidents (41%), agricultural accidents (25%) or
natural disasters (12%). Unfortunately, overall incidence from this
study cannot be ascertained due to lack of a reasonable
denominator.
Estimating temporal incidence trends is similarly challenging,
and data is only available for post-traumatic mucormycosis, of
which the frequency of published case reports has increased
signiﬁcantly between 1993 and 2013 (Lelievre et al., 2014). In an
analysis of all-cause mucormycosis rates in French hospitals,
overall IFI incidence, but not IFI in immunocompetent patients,
increased between 1997 and 2006, suggesting that the rising
incidence of post-traumatic mucormycosis may be attributed to an
increasing proportion of immunocompromised individuals within
this population. Indeed, up to 25% of patients with post-traumatic
IFI may be immunocompromised to some extent (Skiada et al.,
2011; Lelievre et al., 2014).
Post-traumatic IFI may exhibit seasonal and geographical
ﬂuctuations. Two case series in France and Lebanon observed
higher rates of infection in rural areas (Fares et al., 2013; Bitar et al.,
2009), which could be related to differences in hospital resources
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or physician awareness, but also may reﬂect a higher density of
organic material harboring fungi in rural environments (Richard-
son, 2009). Seasonal patterns are more complex. In some cases, IFI
has been diagnosed more frequently during the summer and
autumn months, although the majority of these infections are due
to inhalation rather than trauma (Richardson, 2009; Petrikkos
et al., 2012). Accelerated organic decay during warm, dry periods
may precipitate rapid fungal growth and higher atmospheric spore
concentrations, explaining this observation. In contrast, a 6-year
(1994-2004) retrospective Texan study of 16 patients, 4 with
known trauma, reported a clustering of mucormycosis cases in
February and March, prior to the rainy season and with average
high temperatures rarely exceeding 25 C (Sims and Ostrosky-
Zeichner, 2007). Given that most fungi prefer temperatures in the
range of 12 C to 30 C (Garcia-Solache and Casadevall, 2010), the
relatively hot Texan climate may explain the shift in peak
incidence.
Demographically, IFI occurs over a wide range of ages, with the
mean age in civilian trauma patients between 27 and 48 years
(Table 1) (Neblett Fanfair et al., 2012; Fares et al., 2013; Moran et al.,
2006a; Lelievre et al., 2014). This age distribution is roughly
comparable to that of the general trauma population and reﬂects
occupational age patterns (Heim et al., 2014; Alghnam et al., 2014;
Allen et al., 2015). Most studies observe a male predominance
consistent with both general IFI and trauma populations (Neblett
Fanfair et al., 2012; Nance et al., 2013).
Clinical Course
Military
The vast majority of soldiers with post-traumatic IFI are injured
by explosions during dismounted patrol, leading to severe injuries
and intensive medical interventions (Table 1) (Radowsky et al.,
2015; Lewandowski et al., 2016; Warkentien et al., 2015).
Description of wound characteristics in these patients is often
limited to the presence or absence of necrosis, and recurrent
necrosis was a requirement for inclusion in most studies to better
Table 1
Comparison of civilian and military post-traumatic IFI populations by demographic information, injury patterns, and medical interventions. Values are reported as
proportions of the cohort (%), mean, median, or ranges based on one or more studies. Abbreviations: IED, Improvised Explosive Device; LE, Lower Extremity; UE, Upper
Extremity; ICU, Intensive Care Unit; LOS, Length Of Stay.
Civilian Military
Demographic information
Average* age, years 27–48 Fares et al. (2013),Neblett Fanfair et al. (2012) 22–24 Lloyd et al. (2014), Paolino et al. (2012)
Sex (% male) 46–93% Fares et al. (2013), Neblett Fanfair et al. (2012) 100% Lloyd et al. (2014)
Underlying disease (%) 18–38% Moran et al. (2006a), Neblett Fanfair et al. (2012) –




Bone fracture (%) 34–85% Lelievre et al. (2014), Neblett Fanfair et al. (2012) 80% Lewandowski et al. (2016)
Open bone fracture (%) – 70% Lewandowski et al. (2016)
LE amputation (%) – 79–85% Lewandowski et al. (2016), Rodriguez et al.
(2014a)
UE amputation (%) – 15% Lewandowski et al. (2016)
Clinical characteristics
Fever (%) 20–100% Arnaiz-Garcia et al. (2009), Obradovic-Tomasev et al.
(2016)
95% Warkentien et al. (2012)
Leukocytosis (%) 50–100% Austin et al. (2014), Obradovic-Tomasev et al. (2016) 97% Warkentien et al. (2012)




ICU admission (%) 56–77% Lelievre et al. (2014), Neblett Fanfair et al. (2012) 86–98% Warkentien et al. (2012), Warkentien et al.
(2015)
Surgical amputation (%) 12–83% Lelievre et al. (2014), Vitrat-Hincky et al. (2009) 19–77% Warkentien et al. (2015), Weintrob et al. (2015)
Average* hospital LOS, days 34 Moran et al. (2006a) 48–69 Lloyd et al. (2014), Warkentien et al. (2012)
Massive transfusions, >20 units/24 hours
(%)
– 65% Lewandowski et al. (2016)
Average ICU LOS, days – 2–11 Rodriguez et al. (2014b,c), Warkentien et al.
(2012)
Average* diagnostic and treatment delay in days
Injury to diagnosis 10–19a Austin et al. (2014) 3–0 Lloyd et al. (2014), Warkentien et al. (2012)
Injury to ﬁrst positive culture 14 Neblett Fanfair et al. (2012) 6 Warkentien et al. (2015)
Injury to ﬁrst surgical debridement 1–16a Neblett Fanfair et al. (2012) –
Injury to start of antifungal therapy – 7–15 Lloyd et al. (2014), Paolino et al. (2012)
Sample acquisition to start of antifungal
therapy
0.5–3.4 Neblett Fanfair et al. (2012), Rüping et al. (2009) 4 Warkentien et al. (2012)
Reference citations refer to the original list of references in the full manuscript.
* Average refers to either mean or median values as reported by individual studies.
a These values represent ranges rather than averages.
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capture true IFI cases (De Pauw et al., 2008; Rodriguez et al.,
2014b). Other common physical exam ﬁndings include purulence
and ﬁbrinous exudates (Warkentien et al., 2012).
Delays between injury, diagnosis, and treatment are well-
described as signiﬁcant drivers of patient outcomes. In the military
setting, the average time between injury and date of ﬁrst positive
culture was six days, corresponding to an average delay of 3–10
days between injury and diagnosis (Paolino et al., 2012; Lloyd et al.,
2014; Warkentien et al., 2015). Meanwhile, 7–15 days passed
between injury and initiation of antifungal therapy; this delay was
reduced to four days when measured from sample acquisition
(Warkentien et al., 2012; Paolino et al., 2012; Lloyd et al., 2014).
Civilian
In contrast to military patients, a multitude of injury types and
settings may be seen in civilians with IFI (Table 1). The most
commonly reported antecedent injuries are motor vehicle
accidents, incidents associated with agricultural equipment,
natural disasters, and to a lesser extent, falls (Neblett Fanfair
et al., 2012; Lanternier et al., 2012; Roden et al., 2005; Vitrat-
Hincky et al., 2009; Ingram et al., 2014; Jain et al., 2006). The lower
extremities are the most common site of infection, with the
exception of near-drowning events that precipitate infection in the
lungs and CNS (Katragkou et al., 2007). Almost all post-traumatic
IFIs are categorized as cutaneous, while disseminated and
rhinocerebral infections may occur in rare instances (Lanternier
et al., 2012; Vitrat-Hincky et al., 2009; Bala et al., 2015; Millon et al.,
2016; Rao et al., 2006).
In general, most infectious symptoms, commonly including
fever and leukocytosis, develop within 30 days of injury
(Obradovic-Tomasev et al., 2016; Lelievre et al., 2014; Vitrat-
Hincky et al., 2009; Arnaiz-Garcia et al., 2009; Austin et al., 2014;
Jacobo et al., 2010; Rodríguez-Lobato et al., 2016; Almaslamani
et al., 2009; Chander et al., 2015). Necrosis is the most common
physical exam ﬁnding, occurring in 40–100% of cases, although its
use as an inclusion criteria may artiﬁcially inﬂate this ﬁgure in
certain studies (Lelievre et al., 2014; Ingram et al., 2014; Jain et al.,
2006; Arnaiz-Garcia et al., 2009; Austin et al., 2014; Chander et al.,
2010; Rajakannu et al., 2006; Petrikkos et al., 2003). Ulceration is
the second-most common ﬁnding, occurring in 19-57% of patients
(Lelievre et al., 2014; Chander et al., 2015). Erythema, edema,
induration, purulent discharge, cellulitis, and visible mold may also
be evident, although estimation of frequencies is limited by small
sample sizes (Neblett Fanfair et al., 2012; Lelievre et al., 2014;
Vitrat-Hincky et al., 2009; Austin et al., 2014; Rodríguez-Lobato
et al., 2016; Fang et al., 2016; Kaushik et al., 2012; Li et al., 2013).
The timing of clinical interventions has thus far only been
reported in a small number of civilian studies. In patients injured
during a tornado in Joplin, Missouri, the time between injury and
diagnosis ranged from 10 to 19 days, with a median of 14 days
between injury and collection of the culture that led to diagnosis
(Neblett Fanfair et al., 2012; Austin et al., 2014). In a small case
series, Jacobo et al. (2010) described a 3-day delay between ﬁrst
symptoms and treatment initiation. Two additional studies found
an average of 0.5 and 3.4 days between acquisition of the sample
leading to diagnosis and initiation of antifungal therapy (Neblett
Fanfair et al., 2012; Rüping et al., 2009). However, these estimates
included non-traumatic IFI and patients who were treated prior to
deﬁnitive diagnosis. Overall, when compared to military cohorts,
civilians appear to have a more delayed diagnosis, possibly due to
postponement of sample acquisition, while initiation of antifungal




Post-traumatic IFI in military patients is most often caused by
Mucorales, Aspergillus and Fusarium species, accounting for 34%,
31% and 22% of infections, respectively (Table 2) (Weintrob et al.,
2014). However, Mucorales growth is most predictive of recurrent
necrosis and IFI diagnosis (Lloyd et al., 2014; Rodriguez et al.,
2014c). Within the order Mucorales, Mucor species are the
predominant organisms, followed by Saksenaea and Rhizopus.
The most common Aspergillus species are A. terreus and A. ﬂavus,
accounting for 10% and 9% of all infections, respectively, with A.
Table 2
Fungi isolated from wounds of civilian and military trauma patients diagnosed with IFI.
Civilian Military
Mucorales Aspergillus spp. Mucorales Aspergillus spp.
Actinomucor spp. A. ﬂavum Apophysomyces spp. A. ﬂavum
A. elegans A. fumigatus Lichtheimia spp. A. fumigatus
Apophysomyces spp. Candida spp. Mucor spp. A. niger
A. elegans Exserohilum spp. Rhizopus spp. A. terreus
A. trapeziformis E. rostratum Saksenaea spp.
A. variabilis Fusarium spp. S. erythrospora Acrophialophora spp.
Cunninghamella spp. Scedosporium spp. S. vasiformis A. fusispora
C. bertholletiae S. apiospermum Alternaria spp.
Lichtheimia spp. Beauveria spp.
L. corymbifera Bipolaris spp.
L. ramosa Candida spp.
Mucor spp. Fusarium spp.
M. circinelloides Graphium spp.
M. racemosus Paecilomyces spp.
Rhizomucor spp. Penicillium spp.
R. variabilis Pythium spp.
Rhizopus spp. P. aphanidermatum
R. microsporus Scedosporium spp.
R. oryzae S. proliﬁcans
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fumigatus constituting about 1% of infections (Warkentien et al.,
2015). Other organisms cultured from IFI wounds include
Lichtheimia, Apophysomyces, Aspergillus niger, Bipolaris, Penicillium,
Alternaria, Scedosporium, Graphium, and Candida (Murray et al.,
2011; Warkentien et al., 2012; Paolino et al., 2012; Radowsky et al.,
2015).
Co-infections by both bacteria and other fungi are common.
Bacterial and yeast co-infections occur in 55% of IFI, with 27% of
infections involving MDROs (Lewandowski et al., 2016). The most
common bacteria are Enterococcus and Acinetobacter (Warkentien
et al., 2012). Compared to those without IFI, bacterial co-infections
in IFI wounds occur at a signiﬁcantly higher rate (Lewandowski
et al., 2016). Meanwhile, co-infection with other molds occurs in
27-67% of patients (Paolino et al., 2012; Radowsky et al., 2015;
Warkentien et al., 2015; Akers et al., 2015).
Civilian
Similar to the military population, post-traumatic IFI in civilian
patients is most often due to fungi in the order Mucorales (Table 2).
As a result, most studies detailing species-level identiﬁcation of
infectious agents in this population have been purposefully limited
to cases of mucormycosis. These studies illustrate a predominance
of Apophysomyces, Lichtheimia (previously Absidia), Rhizopus, and
Mucor, whereas infection due to Rhizomucor, Cunninghamella, and
Cokeromyces genera are relatively rare (Gomes et al., 2011). At the
species level, commonly identiﬁed organisms include Rhizopus
oryzae, Lichtheimia corymbifera, Apophysomyces elegans, Apophy-
somyces trapeziformis, Mucor racemosus, and Saksenaea vasiformis
(Neblett Fanfair et al., 2012; Lelievre et al., 2014; Millon et al., 2016;
Arnaiz-Garcia et al., 2009; Chander et al., 2010; Li et al., 2013).
Although Rhizopus oryzae accounts for 70% of all mucormycosis
infections, post-traumatic IFI in general appears to be caused by a
more heterogeneous collection of Mucorales organisms (Kaushik,
2012; Lelievre et al., 2014; Bilal et al., 2016). Aspergillus (esp.
fumigatus), Scedosporium (esp. apiospermum), and Fusarium are
also prevalent pathogens, occasionally overcoming mucormycosis
in frequency (Obradovic-Tomasev et al., 2016; Vitrat-Hincky et al.,
2009; Slavin et al., 2015). Although Candida has been cultured from
traumatic wounds (Obradovic-Tomasev et al., 2016), the role of this
pathogen in IFI remains uncertain.
Meanwhile, rates of bacterial co-infection in cases of mucor-
mycosis vary from 20% to 100% (Neblett Fanfair et al., 2012;
Obradovic-Tomasev et al., 2016; Lelievre et al., 2014; Arnaiz-Garcia
et al., 2009; Austin et al., 2014; Chander et al., 2010) with
involvement of diverse organisms including Staphylococcus aureus,
Escherichia Coli, Pseudomonas, and Enterococcus. Fungal co-infec-
tion, most notably by Candida and other molds, is less common,
occurring in 6-67% of IFI wounds (Neblett Fanfair et al., 2012;
Lelievre et al., 2014; Vitrat-Hincky et al., 2009).
Patient and environmental characteristics may inﬂuence
species frequency. In their cohort of 929 individuals with
mucormycosis, Roden et al. (2005) found a higher rate of
Lichtheimia and Apophysomyces infections in males. The reason
for this observation was unclear, but such a pattern may reﬂect sex-
speciﬁc frequencies of underlying conditions or possible organism-
hormone interactions. Species-speciﬁc geographical clustering
was demonstrated by Neblett Fanfair et al. (2012), who found that
all thirteen cases of mucormycosis following the Joplin tornado
were due to Apophysomyces trapeziformis. The authors posited that
spores from one or more environmental sources along the tornado
path were aerosolized and inoculated into injured individuals.
Similarly, Lu et al. (2009) found that all six cases of Rhizomucor




Risk factors speciﬁc to military personnel are largely derived
from a case-control analysis within the TIDOS cohort which found
that massive transfusion (>20 U/24 hours), blast injury, dis-
mounted status, and above-knee amputations were associated
with IFI (Table 3) (Rodriguez et al., 2014a). These risk factors may
partially explain why the majority of IFI cases during this time
period were clustered in the southern region of Afghanistan, where
injury severity and massive transfusion requirements were greater
(Tribble et al., 2015). Compared to other regions of the country,
southern Afghanistan has a lower elevation and more temperate
climate (average annual mean temperature 18.8 C), suggesting a
possible environmental component driving IFI in this population
as well (Tribble et al., 2015). Furthermore, although the frequency
of underlying conditions in this population is extremely low, the
high severity of injuries and subsequent need for interventions
such as ICU admission and broad-spectrum antibiotics may have
contributed to a temporary immunosuppressed state. In addition,
severe trauma itself may produce local and systemic immunosup-
pression as a result of dysregulated immune responses (Kimura
et al., 2010).
Civilian
Immunosuppression in the civilian population is well-known to
predispose patients to IFI (Cornely, 2008). Investigation of risk
factors associated with post-traumatic IFI in previously immuno-
competent patients, however, is limited (Table 3). In a case-control
study of patients injured during the Joplin tornado, patients with
IFI had a greater number of wounds, were more likely to have
penetrating wounds, and were more frequently diagnosed with
rhabdomyolysis on admission compared to controls with broken
skin but no evidence of IFI (Neblett Fanfair et al., 2012). Larger
wound burden may represent increased injury severity, while
penetrating wounds may be at greatest risk of inoculation by
fungal elements (Hajdu et al., 2009). Acidosis, which occurs in
severe rhabdomyolysis, is known to impair phagocyte function and
cause release of free iron from sequestering proteins (Spellberg
et al., 2005).
Other predisposing factors may be inferred from observational
studies. Wound contamination, for example, is considered a
prerequisite for post-traumatic IFI based on the proposed
pathogenic mechanism (Richardson, 2009). Ingram et al. (2014)
found that all motor vehicle accidents leading to IFI involved either
motorcyclists or unrestrained passengers, who presumably were at
Table 3
Risk factors associated with post-traumatic IFI development. Included are factors
associated with IFI in single civilian (Spellberg et al., 2005) and military (Neblett
Fanfair et al., 2012) case-control studies and factors that were qualitatively
associated with IFI in non-comparative observational studies (Lanternier et al.,
2012; Skiada et al., 2012; Lewandowski et al., 2016; Gomes et al., 2011).
Civilian Military
Number of wounds Massive transfusion (> 20 units/24 hr)
Penetrating wounds Blast injury
Rhabdomyolysis Dismounted status
Wound contamination Above-knee traumatic amputation
Synthetic clothing Base deﬁcit  10 mcg/La
Shock index  1.5a
Temperate climate
Reference citations refer to the original list of references in the full manuscript.
a These factors were found to be statistically signiﬁcant in univariate analyses
conducted by Rodriguez et al. (2014a) but were subsequently removed from the
multivariate analysis due to collinearity with the transfusion variable.
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high risk of wound contamination by soil, plant matter, and gravel.
Likewise, Lelievre et al. (2014) found that 100% of IFIs due to minor
injury occurred in wounds with gross soil contamination. Fares
et al. (2013) qualitatively observed that patients wearing synthetic
fabric at the time of injury were more likely to develop IFI
compared to those wearing cotton, possibly due to increased
warmth and moisture on the skin. Finally, underlying conditions
(older age, diabetes, medication use, chronic end-organ disease),
medical interventions, and severe trauma conferring additional




Diagnosis of post-traumatic IFI is standardized in the military
literature and requires clinical and laboratory measures (Table 4)
(Warkentien et al., 2012; De Pauw et al., 2008). Laboratory
conﬁrmation of IFI is a critical component of diagnosis, but current
methods may give rise to missed diagnoses or delays in treatment.
Positive culture is obtained in 82-91% of cases, while histopathol-
ogy specimens are positive 83% of the time (Warkentien et al.,
2015; Rodriguez et al., 2014c; Warkentien et al., 2012). In one study,
positive histopathology during the initial hospital admission was
predictive of an IFI diagnosis, whereas culture positivity was not,
perhaps due to a higher false positive rate associated with fungal
culture (Lloyd et al., 2014).
Early diagnosis is critical in the management of IFI. New
techniques may provide a more rapid diagnosis, but widespread
implementation is often hindered by cost and decreased sensitivity
or speciﬁcity. For example, frozen sections have a positive
predictive value of 92% and negative predictive value of 87%
when compared to permanent sections (Warkentien et al., 2012;
Heaton et al., 2016). Protocols for early screening may provide an
alternate avenue to minimize delays between injury, diagnosis,
and treatment. Implementation of the “Blast” screening guideline
triggering biopsy for histopathology and culture in high-risk
patients in a German military hospital accelerated time to
diagnosis and treatment, with suggested improvements in clinical
outcomes including mortality (Lloyd et al., 2014). In this setting,
“at-risk” patients were deﬁned as those with bilateral lower
extremity amputation secondary to blast injury, large amputation
burden, more than expected soft tissue necrosis, extensive wound
contamination, and/or required signiﬁcant amputation revision.
Civilian
IFI diagnosis in civilians is subject to a high degree of
interpretation across institutions and studies, but typically
requires laboratory conﬁrmation of infection in the appropriate
clinical context. Laboratory analysis often involves culture and
histopathology as seen in military hospitals, but may also include
direct microscopic examination with special stains and molecular
methods such as polymerase chain reaction (PCR). Meanwhile, the
threshold for clinical suspicion is not standardized (Montagna
et al., 2013). Studies may include patients based on International
Classiﬁcation of Diseases (ICD) codes, which could lead to the
inclusion of patients without true IFI (Bitar et al., 2009).
In case series, histopathology is the most common method of
laboratory diagnosis, followed by culture (Neblett Fanfair et al.,
2012; Roden et al., 2005; Obradovic-Tomasev et al., 2016; Jain et al.,
2006; Arnaiz-Garcia et al., 2009; Austin et al., 2014; Jacobo et al.,
2010; Almaslamani et al., 2009; Chander et al., 2015; Chander et al.,
2010; Rajakannu et al., 2006; Slavin et al., 2015; Yue et al., 2013;
Marques et al., 2012). Independently, neither method is completely
satisfactory. Cultures are positive in 20-100% of patients, as
compared to 82-91% in military cohorts (Vitrat-Hincky et al., 2009;
Arnaiz-Garcia et al., 2009). This wider distribution may result from
less restrictive deﬁnitions of IFI as well as greater variation in
protocols for specimen collection. Meanwhile, false negative
cultures occur in 17-56% of wounds with positive histopathology,
and 11% of histopathology samples from wounds with positive
culture are negative (Lanternier et al., 2012; Vitrat-Hincky et al.,
2009; Jain et al., 2006). While histopathology can often be used to
identify the fungus, misdiagnosis is not uncommon. In a
comparison of surgical pathology reports to microbiological
culture results, 10 (21%) cases were misdiagnosed by histopathol-
ogy - eight misclassiﬁed by division (e.g. Aspergillus vs. Rhizopus)
and two by genus (e.g. Mucor vs. Rhizopus) (Sangoi et al., 2009).
Together, these data support the simultaneous use of histopathol-
ogy and culture to maximize accurate diagnoses.
As previously discussed, IFI is a time-sensitive diagnosis. In the
civilian literature, histopathology is commonly available within
24 hours of sample acquisition (Moran et al., 2006a), while culture
growth occurs on average 2 to 7 days after the initial wound
debridement (Moran et al., 2006a; Ingram et al., 2014). PCR may
provide the most rapid diagnosis, with positive results obtained an
average of 9 days before sample collection for culture or
histopathology (Millon et al., 2016). Unfortunately, no data for
the use of PCR in post-traumatic IFI is available, and the sensitivity
is relatively low (56-81%) in patients with mucormycosis of any
cause (Millon et al., 2016; Rüping et al., 2009). Therefore, while
more frequent use of molecular methods could speed diagnosis,
issues of test validity, cost and pre-test clinical suspicion remain.
Although earlier screening of high-risk patients improved time to
diagnosis in military settings, the authors are not aware of similar
protocols being applied in civilian trauma care. Implementation of
screening protocols for civilians would be an inexpensive and
potentially effective method for reducing delays in diagnosis and
improving outcomes. However, a modiﬁed deﬁnition for an “at-
risk” patient would be required to accurately reﬂect the different
patterns of injury seen in military and civilian settings.
Treatment
Military
Early surgical debridement and systemic antifungal therapy
constitute the gold standard of treatment for IFI in both military
and civilian populations (Rodriguez et al., 2014c; Gomes et al.,
2011). The empirical evidence for such therapy is generally
supportive, although methodological issues impede deﬁnitive
conclusions. For example, although surgical debridement is often
associated with a better prognosis, lack of controlled studies makes
it difﬁcult to differentiate between true improvement and
confounding by indication (Lanternier et al., 2012; Bala et al.,
2015; Chakrabarti et al., 2009; Shoham et al., 2010). That is to say,
Table 4
Post-traumatic IFI criteria used in military cohorts, modiﬁed from the European
Organization for Research and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy and Infectious Diseases
Mycoses Study Group (EORTC/MSG) IFI deﬁnitions (Murray et al., 2011; Allen et al.,
2015).
Military Criteria for IFI Diagnosis
(1) Presence of traumatic wound
(2) Recurrent necrosis on  2 consecutive surgical debridements
(3) Evidence of IFI by culture or histopathology
Reference citations refer to the original list of references in the full manuscript.
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surgical debridement may not be undertaken in patients with
disseminated disease or risk of imminent death who are by
deﬁnition predisposed to worse outcomes. Likewise, the utility of
antifungal therapy has been questioned by some authors given
limited wound tissue penetration in the setting of vessel
thrombosis (Spellberg et al., 2005). However, observational studies
have shown reduced mortality (Roden et al., 2005; Vitrat-Hincky
et al., 2009; Millon et al., 2016). Despite doubts raised about the
true effectiveness of these interventions, most experts support the
combined surgical and pharmaceutical approach.
Treatment of IFI in the military cohort generally follows this
standard. Essentially all patients underwent surgical debridement,
with an average of 9 procedures per patient, and at least 84% of
patients additionally received an antifungal drug, most commonly
amphotericin B with or without voriconazole, for a median of 22
days (Lewandowski et al., 2016; Weintrob et al., 2014). Dakin’s
solution has performed well in in vitro studies and was a common
adjuvant treatment, received by 32% of patients in one series
(Rodriguez et al., 2014c; Barsoumian et al., 2013).
Civilian
Similar to the military cohort, greater than 90% of civilian
patients undergo surgical debridement, with a large proportion
requiring multiple debridements (Lelievre et al., 2014). The most
common antifungal therapy given in case series is amphotericin B,
either in conventional or lipid form, often followed by a triazole
(i.e. posaconazole). Although liposomal amphotericin B is pre-
ferred due to lower toxicity and some, albeit mixed, evidence of
improved effectiveness and survival (Sims and Ostrosky-Zeichner,
2007; Rüping et al., 2009), deoxycholate amphotericin B is
commonly used because of availability and lower cost. In surviving
patients, antifungal therapy is usually administered for a period of
several months after diagnosis, with a median duration of
treatment between 23 and 55 days in two series (Skiada et al.,
2011; Lelievre et al., 2014; Arnaiz-Garcia et al., 2009). Compared to
soldiers, civilians appear to receive a longer course of antifungals,
possibly reﬂecting higher rates of comorbidities and variability in
local guidelines.
Other less frequently used adjunctive therapies include
hyperbaric oxygen, topical solutions such as Dakin’s, deferasirox,
and, most recently, immune-modulating agents such as interferon-
g and nivolumab (Roden et al., 2005; Vitrat-Hincky et al., 2009;
Almaslamani et al., 2009; Yue et al., 2013; Grimaldi et al., 2017).
Evidence for the effectiveness of these therapies is limited and
mixed. Hyperbaric oxygen and Dakin’s solution have been shown
to have antifungal effects in vitro, but only a handful of lower
quality studies, which suggest possible improved outcomes, have
examined their use in the clinical setting (Barsoumian et al., 2013;
Tragiannidis and Groll, 2009; Lewandowski et al., 2013). Adjunc-
tive deferasirox, which theoretically reduces fungal access to iron
through its chelating ability and appeared promising in open-label
studies, was actually associated with a higher 90-day mortality
compared to placebo in a randomized controlled trial (Spellberg
et al., 2012). However, this trial was limited by small sample size,
unequal baseline characteristics, and a patient population with
high rates of hematologic malignancy and other immunosuppres-
sive states that are not reﬂected in the post-traumatic IFI
population. Immune-modulating agents are some of the newest
additions to the antifungal armamentarium, but are currently only
supported by success in case reports.
Unfortunately, almost no prospective trials have been con-
ducted to compare the effectiveness of different antifungal
regimens and, as a result, the optimal therapeutic approach to
IFI in trauma and other populations is not known.
Outcomes
Military
The overall mortality rate for military personnel with IFI is 7.8%,
with other estimates ranging from 6% to 14% depending on case
deﬁnitions. Despite relatively high survival, morbidity in surviving
patients is substantial. Surgical amputation, an important patient-
centered outcome, is required in 19–77% of surviving patients
(Warkentien et al., 2015; Weintrob et al., 2014). The median total
hospital length of stay is 48–69 days, with a median of 2 to 11 days
spent in the ICU and an average of 16 days to initial wound closure
(Warkentien et al., 2012; Lloyd et al., 2014).
Compared to non-infected trauma patients, patients with IFI
typically have poorer outcomes. Trends towards higher mortality
in IFI patients and those with higher likelihood of IFI (recurrent
necrosis or proven/probable status) were apparent in several case-
control studies (Lloyd et al., 2014; Lewandowski et al., 2016;
Weintrob et al., 2014; Rodriguez et al., 2014c). For example,
Lewandowski et al. (2016) found a 6% mortality rate in IFI cases
compared to 1% for non-IFI controls. Although these differences
were not signiﬁcant, no study included more than 100 IFI cases,
which may have masked true differences in mortality.
Morbidity in patients with IFI follows a similar pattern.
Compared to non-IFI controls, patients with IFI have more surgical
amputations, spend more days in the ICU, experience signiﬁcant
delays in initial wound closure, and are more likely to develop
complications requiring repeat surgery after wound closure (Lloyd
et al., 2014; Lewandowski et al., 2016; Warkentien et al., 2015).
Among IFI patients, Mucorales infection, massive transfusions, ICU
admission, and SSTIs are associated with increased time to wound
closure (Lewandowski et al., 2016; Warkentien et al., 2015).
Civilian
The overall mortality rate in trauma patients is 25–41% (Neblett
Fanfair et al., 2012; Skiada et al., 2011; Roden et al., 2005; Lelievre
et al., 2014; Vitrat-Hincky et al., 2009), although some smaller
series report survival of all patients (Yue et al., 2013; Moran et al.,
2006b). Most deaths tend to occur within 2 weeks of hospital
admission or diagnosis (Neblett Fanfair et al., 2012; Austin et al.,
2014; Rajakannu et al., 2006; Slavin et al., 2015). Compared to
combat-injured patients, the civilian mortality rate is substantially
higher, perhaps reﬂecting differences in underlying health status.
When comparing civilian patients with traumatic wounds who did
and did not develop IFI, those with IFI have a 6.7 fold higher
mortality rate (Neblett Fanfair et al., 2012).
As in military cohorts, morbidity is signiﬁcant. The rate of
amputation varies between 12% and 83%, roughly comparable to
that seen in soldiers (Lelievre et al., 2014; Vitrat-Hincky et al.,
2009). Although no valid comparison of amputation rates in non-
IFI civilian trauma patients exists, an estimated 24% of all trauma
affects the extremities, and only 1% of all trauma patients require
limb amputation (Moini et al., 2009). Patients have prolonged
hospital stays, with one study reporting an average of 34 days in
those with upper extremity mucormycosis (Moran et al., 2006a).
While the majority of surviving patients recover within 1.5 months
(Chander et al., 2010; Chakrabarti et al., 2003), Moran et al. (2006a)
found that only 43% of patients had returned to work after an
average of 37 months of follow-up, suggesting that IFIs may have
long-term implications that have not been fully captured by the
present literature.
Some evidence exists for fungal species-speciﬁc outcomes, but
these analyses are scarce and inconsistent. While one study of
mucormycosis found that mortality rates were comparable
between Mucor/Rhizopus, Rhizomucor, and Lichtheimia infections
108 R. Kronen et al. / International Journal of Infectious Diseases 62 (2017) 102–111
(Millon et al., 2016), Cunninghamella infections were associated
with a higher risk of mortality in another study not limited to
trauma (Roden et al., 2005). In a series from Australia, Slavin et al.
(2015) only found dematiaceous molds to be associated with
reduced mortality, while no species-speciﬁc differences within the
Mucorales order were evident.
Future Directions
Current knowledge of post-traumatic IFI leaves much to be
elucidated. The literature is saturated with case series and other
lower quality studies, while large comparative trials are scarce.
Methodological quality hinges on consistent and reliable data
collection, which is often lacking in the IFI population. Thus, to
support the success of future research, improvements in IFI
reporting should be undertaken. The deﬁnition of post-traumatic
IFI, which is well-established in military studies, should be
consistently characterized in the civilian literature. Although
wound aspects such as evidence of angioinvasion and recurrent
necrosis should be equivalent for military and civilian patients, the
wider variety of injuries seen in civilians, including minor injuries
and chronic infection development, may warrant restriction to
speciﬁc injury types and time frames. Furthermore, the role of
newer diagnostic modalities such as PCR and other molecular or
serologic tests should be addressed. If a modiﬁed version of the
EORTC/MSG criteria is to be utilized, then this deﬁnition should be
validated in civilian cohorts and endorsed by experts in civilian
trauma and infectious disease. In conjunction, standardized
national and international protocols for reporting IFI based on
these deﬁnitions will signiﬁcantly improve the capacity for
developing and conducting expanded studies. Civilian IFI registries
are instrumental to this research because recruiting patients with a
rare disease for appropriately-powered studies may otherwise
quickly exceed available ﬁnancial resources and time constraints.
Furthermore, accurate estimates of incidence and distribution can
clarify the effect of environmental, geographical, and climactic
patterns on post-traumatic IFI.
Beyond more appropriate case capture, diagnosis and treat-
ment of post-traumatic IFI may beneﬁt from improved prediction
of IFI development, discovery and incorporation of more rapid
diagnostic methods, and head-to-head comparisons of interven-
tions. Although several risk factors have already been identiﬁed in
the military literature, predisposing characteristics in civilians
have only been suggested by small case-control studies (Neblett
Fanfair et al., 2012). Future researchers seeking to expand this topic
can use risk prediction methods to corroborate these ﬁndings in
larger cohorts as well as develop and incorporate novel methods of
early IFI detection such as serological biomarkers. Technological
advancements in molecular assay methods can also be applied to
the goal of early post-traumatic IFI diagnosis (Millon et al., 2016;
Mery et al., 2016). The accuracy and utility of these assays should
be assessed in relation to the current standards of diagnosis by
culture and histopathological analysis. Finally, our current
treatment strategies are without a strong evidence base. Animal
and human comparative trials are needed, not only to compare
commonly used therapies, but also to explore the effectiveness of
adjunctive treatments (e.g. hyperbaric oxygen), prophylactic
methods, and empiric therapy in high-risk patients (Spellberg
et al., 2005; Trzaska et al., 2015).
Conclusion
Invasive fungal infections are a rare but potentially devastating
infection complicating traumatic wounds. Patients typically
present with necrosis and are diagnosed based on high clinical
suspicion and laboratory analysis of tissue. The presence of post-
traumatic IFI may lead to higher rates of mortality and worse
clinical outcomes. Treatment usually consists of early surgical
debridement and systemic antifungal therapy. Future research
should focus on further illumination of risk factors, improved
diagnostic methods, and optimal treatment regimens. Additional-
ly, comparative and higher-quality evidence is needed to conﬁrm
the ﬁndings from observational studies.
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